Glucotrack hit with dual Nasdaq delisting warnings

Glucotrack, Inc. has received two Nasdaq deficiency notices that together threaten its continued listing on The Nasdaq Capital Market.

Rhea-AI Filing Summary

Glucotrack, Inc. has received two Nasdaq deficiency notices that together threaten its continued listing on The Nasdaq Capital Market. The first relates to failure to meet the $1.00 per share minimum bid price requirement under Nasdaq Rule 5550(a)(2). The second, based on its Form 10-Q for the period ended March 31, 2026, states the company no longer meets the $2,500,000 minimum stockholders’ equity requirement under Listing Rule 5550(b)(1) and does not qualify under alternative standards.

The company plans to timely request a hearing before a Nasdaq Hearings Panel by May 18, 2026, which will temporarily stay delisting while it presents a plan to regain compliance. The filing cautions there is no assurance the appeal will succeed or that Glucotrack will be able to regain or maintain compliance with Nasdaq listing rules.

Positive

• None.

Negative

• Nasdaq delisting risk has escalated, with Glucotrack cited for both sub‑$1.00 bid price and failure to meet the $2,500,000 minimum stockholders’ equity requirement, materially increasing uncertainty around its continued Nasdaq listing and potential future liquidity.

Insights

Equity markets analyst

Dual Nasdaq deficiencies put Glucotrack’s listing at clear risk.

Glucotrack, Inc. now faces two separate Nasdaq issues: its share price has stayed below the $1.00 minimum bid and its Form 10-Q shows stockholders’ equity below $2,500,000. Nasdaq Staff has cited both as bases for delisting.

The company intends to request a hearing with a Nasdaq Hearings Panel by May 18, 2026, which will pause delisting while it presents a compliance plan. Actual outcomes will depend on the Panel’s decision and Glucotrack’s ability to improve its equity and share price metrics.

If the appeal does not succeed, Glucotrack’s shares could be removed from The Nasdaq Capital Market, which often affects trading liquidity and access to capital. Subsequent SEC filings may provide more detail on any remediation steps tied to the bid price and equity shortfalls.

8-K Event Classification

2 items: 3.01, 9.01

2 items

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Minimum bid price requirement: $1.00 per share Minimum stockholders’ equity threshold: $2,500,000 Hearing request deadline: May 18, 2026 +2 more

5 metrics

Minimum bid price requirement $1.00 per share Nasdaq Rule 5550(a)(2) Bid Price Rule

Minimum stockholders’ equity threshold $2,500,000 Nasdaq Listing Rule 5550(b)(1) requirement

Hearing request deadline May 18, 2026 Date by which Glucotrack intends to request Nasdaq hearing

First Staff Determination date May 11, 2026 Initial Nasdaq notice on Bid Price Rule noncompliance

Second Nasdaq letter date May 15, 2026 Additional deficiency based on stockholders’ equity

Key Terms

Bid Price Rule, Minimum Stockholders’ Equity Requirement, Nasdaq Hearings Panel, Emerging growth company, +1 more

5 terms

Bid Price Rule regulatory

"requires listed securities to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”)"

Minimum Stockholders’ Equity Requirement financial

"no longer meets the $2,500,000 minimum stockholders’ equity requirement for continued listing set forth under Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”)"

Nasdaq Hearings Panel regulatory

"request a hearing before a Nasdaq Hearings Panel (the “Panel”) by May 18, 2026, to appeal"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

Emerging growth company regulatory

"Emerging growth company Item 3.01 Notice of Delisting or Failure to Satisfy"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

forward-looking statements regulatory

"contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq listing issues does Glucotrack (GCTK) currently face?

Glucotrack faces two Nasdaq deficiencies: its stock has not met the $1.00 minimum bid price and its latest Form 10-Q shows stockholders’ equity below $2,500,000. Nasdaq Staff has cited both as bases to consider delisting the company’s shares.

How is Glucotrack (GCTK) responding to the Nasdaq delisting notices?

Glucotrack plans to request a hearing before a Nasdaq Hearings Panel by May 18, 2026. A timely request will stay further delisting actions during the process, allowing the company to present its plan to regain compliance with Nasdaq listing requirements.

Which specific Nasdaq rules has Glucotrack (GCTK) failed to satisfy?

Glucotrack no longer complies with Rule 5550(a)(2), requiring a $1.00 minimum bid price, and Rule 5550(b)(1), requiring at least $2,500,000 stockholders’ equity. The filing also notes it does not meet the alternative market value or net income standards.

Does the Nasdaq hearing guarantee Glucotrack (GCTK) will remain listed?

The hearing does not guarantee continued listing. Glucotrack explicitly states there can be no assurance its appeal will be successful, that the Panel will grant continued listing, or that it will regain or maintain compliance with Nasdaq requirements after the hearing.

What could happen to Glucotrack (GCTK) stock if it cannot regain Nasdaq compliance?

If Glucotrack cannot regain compliance and its appeal fails, Nasdaq may delist its securities from The Nasdaq Capital Market. Delisting typically moves trading to less prominent markets and can affect liquidity and access to institutional capital.

What financial threshold did Glucotrack’s latest Form 10-Q reveal it no longer meets?

The Form 10-Q for the period ended March 31, 2026 showed Glucotrack no longer meets Nasdaq’s $2,500,000 minimum stockholders’ equity requirement. This shortfall, combined with prior bid price issues, now forms an additional basis for potential delisting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:45 PM Learn about SEC filing dates

false 0001506983 0001506983 2026-05-15 2026-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2026

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41141		98-0668934
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification No.)

301 Rte. 17 North, Ste. 800, Rutherford, NJ		07070
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 842-7715

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		GCTK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on May 11, 2026, Glucotrack, Inc. (the “Company”) received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Bid Price Rule”), and that the Nasdaq staff (the “Nasdaq Staff”) had determined to delist the Company’s securities from The Nasdaq Capital Market. The Company intends to timely request a hearing before a Nasdaq Hearings Panel (the “Panel”) by May 18, 2026, to appeal Nasdaq Staff’s determination. A timely hearing request will stay any further delisting actions through the hearing process. At the hearing, the Company expects to present its plan to regain compliance with the Bid Price Rule.

On May 15, 2026, the Company received a second letter from Nasdaq notifying the Company that its Form 10-Q for the period ended March 31, 2026, indicates that the Company no longer meets the $2,500,000 minimum stockholders’ equity requirement for continued listing set forth under Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”), and the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. Accordingly, the failure to comply with the Minimum Stockholders’ Equity Requirement has become an additional basis for delisting. The Nasdaq Staff further notified the Company that failure to meet the Minimum Stockholders’ Equity Requirement will be considered in its decision regarding the Company’s continued listing on The Nasdaq Capital Market. The Company intends to present its views with respect to this additional deficiency to the Panel at its hearing. There can be no assurance that the Company will be successful in its appeal, that the Panel will grant the Company’s request for continued listing, or that the Company will be able to regain or maintain compliance with any applicable Nasdaq listing requirements.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this Current Report on Form 8-K include, without limitation, statements regarding the Company’s intent or ability to regain compliance with the Bid Price Rule and the Minimum Stockholders’ Equity Requirement, the outcome of the Nasdaq hearing and appeal process, and the ability for the common stock to remain listed on Nasdaq. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 30, 2026, as well as discussions of potential risks, uncertainties and other important factors in any subsequent Company filings with the SEC. All information in this Current Report on Form 8-K is as of the date of the filing; the Company undertakes no duty to update this information unless required by law.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2026
	GLUCOTRACK, INC.
	By:	/s/ Paul Goode
	Name:	Paul Goode
	Title:	Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB